diabetic patients with ischemic cerevrobascular diseases
Conditions
Interventions
cilostazol 200 mg/day
aspirin 100 mg/day
Sponsors
Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) diabetic subjects 2) patients with ischemic cerebrovascular diseases diagnosed with magnetic resonance imaging 3) patietns who agreed to participate with written informed consent 4) patietns is or older than 20-years old when agreed to participate
Exclusion criteria
Exclusion criteria: 1) patients who is treated with cilostazol 2) patients who suffers from bleeding disorders 3) patients with unstable congestive heart failure or angina pectoris 4) patients with allergy against cilostazol 5) pqtients with allergy against aspirin 6) patients with cardiac diseases associated with cereberal embolism 7) patients with malignant diseases or hard to be followed 8) patients who are judged to be inappropriate for inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating endothelial progenitor cells, markers of oxidative stress | — |
Secondary
| Measure | Time frame |
|---|---|
| cerevrovascular events, the extent of lacuna stroke | — |
Countries
Japan
Contacts
Public ContactHidenori Koyama
Osaka City University Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine
Outcome results
None listed